

ABBVIE INC.

ISIN: **US00287Y1091**

WKN: **00287Y109**

Overview

2024/05/24 16:31:49

Price

144.98 EUR

Difference



-1.71% (-2.52)

General attributes

ISIN US00287Y1091

Symbol ABBV

Exchange Frankfurt

Currency EUR

Sector Chemical / Pharmaceutical / Health

Security type Stock

Market cap (m) 258,483 EUR

Benchmark S&P 500

Market data

Bid (Bid size) 144.18 EUR (40)

Ask (Ask size) 144.64 EUR (40)

Open 145.82 EUR

High 146.70 EUR

Low 144.98 EUR

Close (prev. day) 147.50 EUR

VWAP 146.48976 EUR

Volume (pcs) 123

Trading volume 18,018.24

Number of trades 5

Last size 8

Futures and Options

Related Futures 15

Related Options -

PDF Downloads

Company report: ABBVIE INC.



5Y



Information about previous performance does not guarantee future performance.

Source: FactSet

Recent research

| on instrument | on sector | on market | |
|---------------|-----------|-----------------------|----------|
| Date | | Headline | Download |
| 2024/04/26 | | Global Equity Ratings | |
| 2024/04/03 | | Global Equity Ratings | |
| 2024/03/13 | | Global Equity Ratings | |
| 2024/02/22 | | Global Equity Ratings | |
| 2024/02/14 | | Global Equity Ratings | |

Details

2024/05/24 16:31:49

Price

144.98 EUR

Difference 📉 -1.71% (-2.52)

General attributes

| | |
|----------------|------------------------------------|
| ISIN | US00287Y1091 |
| Symbol | ABBV |
| Exchange | Frankfurt |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 258,483 EUR |
| Benchmark | S&P 500 |

Market data

| | |
|-------------------|-----------------|
| Bid (Bid size) | 144.18 EUR (40) |
| Ask (Ask size) | 144.64 EUR (40) |
| Open | 145.82 EUR |
| High | 146.70 EUR |
| Low | 144.98 EUR |
| Close (prev. day) | 147.50 EUR |
| VWAP | 146.48976 EUR |
| Volume (pcs) | 123 |
| Trading volume | 18,018.24 |
| Number of trades | 5 |
| Last size | 8 |

Performance and Risk

| | 6m | 1Y | 3Y |
|-------------|---------|---------|---------|
| Perf (%) | +15.51% | +11.74% | +53.58% |
| Perf (abs.) | +19.80 | +15.50 | +51.46 |
| Beta | 0.45 | 0.31 | 0.34 |
| Volatility | 21.21 | 22.01 | 25.62 |

5Y



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

| | |
|---|-------------------------|
| Ø price 5 days Ø volume 5 days (pcs.) | 150.02 EUR (174) |
| Ø price 30 days Ø volume 30 days (pcs.) | 151.91 EUR (146) |
| Ø price 100 days Ø volume 100 days (pcs.) | 156.72 EUR (230) |
| Ø price 250 days Ø volume 250 days (pcs.) | 142.86 EUR (222) |
| YTD High date | 168.80 EUR (2024/04/02) |
| YTD Low date | 141.40 EUR (2024/01/02) |
| 52 Weeks High date | 168.80 EUR (2024/04/02) |
| 52 Weeks Low date | 119.00 EUR (2023/07/13) |

All listings for ABBVIE INC.

| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
|-----------------------|------------|-------|------------|-----------------------|------------------|
| Xetra | 2024/05/24 | 17:35 | 145.16 EUR | 0.09 | 21 |
| Vienna Stock Exchange | 2024/05/24 | 17:32 | 145.14 EUR | 0.00 | 2 |
| Tradegate | 2024/05/24 | 20:12 | 144.54 EUR | 0.36 | 71 |
| Stuttgart | 2024/05/24 | 19:38 | 144.42 EUR | 0.05 | 8 |

| | | | | | |
|---|----------------|-------|--------------|--------|--------|
| NYSE | 2024/ 05/24 | 20:13 | 156.7342 USD | 246.80 | 40,656 |
| Munich | 2024/ 05/24 | 08:09 | 146.68 EUR | 0.00 | 1 |
| London Stock Exchange European Trade Reporting | 2024/ 05/24 | 17:30 | 158.01 USD | 0.00 | 8 |
| Frankfurt | 2024/ 05/24 | 16:31 | 144.98 EUR | 0.02 | 5 |
| Euronext Milan MTF Trading After Hours | 2024/ 03/21 | 19:49 | 162.60 EUR | 0.01 | 2 |
| Euronext Milan MTF Global Equity Market | 2024/ 05/24 | 17:44 | 145.42 EUR | 0.00 | 1 |
| Duesseldorf | 2024/ 05/24 | 19:30 | 144.42 EUR | 0.00 | 6 |
| Berlin | 2024/ 05/24 | 19:35 | 144.70 EUR | 0.00 | 15 |

Company profile

Company Logo



Contact Details

ABBVIE INC.

--

1 North Waukegan Road - 60064-6400 North Chicago

Telefon: +1-847-932-7900

Fax: +

E-mail: -

PDF Downloads

Company report: ABBVIE INC.



Company Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Members of Management Board

| | |
|-----------------------|-------------------------------|
| Robert Alpern | Member of Board of Directors |
| Susan Quaggin | Member of Board of Directors |
| Brett Hart | Member of Board of Directors |
| Edward Rapp | Member of Board of Directors |
| Frederick Waddell | Member of Board of Directors |
| Glenn Tilton | Member of Board of Directors |
| Jennifer Davis | Member of Board of Directors |
| Melody Meyer | Member of Board of Directors |
| Rebecca Roberts | Member of Board of Directors |
| Roxanne Austin | Member of Board of Directors |
| Thomas Freyman | Member of Board of Directors |
| William Burnside | Member of Board of Directors |
| Richard A. Gonzalez | Chairman of Managing Board |
| Azita Saleki-Gerhardt | Member of Executive Committee |
| Jeffrey R. Stewart | Member of Executive Committee |
| Nicholas Donoghoe | Member of Executive Committee |
| Perry C. Siatis | Member of Executive Committee |
| Robert A. Michael | Member of Executive Committee |
| Scott Reents | Member of Executive Committee |
| Timothy J. Richmond | Member of Executive Committee |

